<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Simvastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00641</strong>&#160; (APRD00104)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl <span class="caps">COA</span> reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic <span class="caps">LDL</span> receptors, it increases breakdown of <span class="caps">LDL</span> cholesterol. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00641/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00641/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00641.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00641.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00641.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00641.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00641.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00641">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Simvastatina</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Simvastatine</td><td>French</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Simvastatinum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Synvinolin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cholestat</td><td>Kalbe</td></tr><tr><td>Colemin</td><td>Biohorm</td></tr><tr><td>Labistatin</td><td>Sandoz</td></tr><tr><td>Lipex</td><td>Merck Sharp &amp; Dohme</td></tr><tr><td>Lodales</td><td>Sanofi-Aventis</td></tr><tr><td>Medipo</td><td>Mediolanum Farmaceutici</td></tr><tr><td>Nivelipol</td><td>Temis-Lostalo</td></tr><tr><td>Simovil</td><td>Merck Sharp &amp; Dohme</td></tr><tr><td>Sinvacor</td><td>Merck Sharp &amp; Dohme</td></tr><tr><td>Sivastin</td><td>Sigma-Tau</td></tr><tr><td>Sivatin</td><td>Rowex</td></tr><tr><td>Sivinar</td><td>Anfarm</td></tr><tr><td>Sorfox</td><td>Galex</td></tr><tr><td>Sotovastin</td><td>Bros</td></tr><tr><td>Starezin</td><td>Leovan Pharmaceuticals</td></tr><tr><td>Starstat</td><td>Lupin</td></tr><tr><td>Starzoko</td><td>Daewoong</td></tr><tr><td>Stasiva</td><td>Pharmanel</td></tr><tr><td>Statex</td><td>Pliva</td></tr><tr><td>Staticor</td><td>Darnitsa</td></tr><tr><td>Statinal</td><td>Alet Pharmaceuticals</td></tr><tr><td>Stativer</td><td>Iapharm</td></tr><tr><td>Zocor</td><td>Merck &amp; Co</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Inegy</td><td>Simvastatin + Ezetimibe</td></tr><tr><td>JUVISYNC</td><td>Simvastatin + Sitagliptin</td></tr><tr><td>Simcor</td><td>Niacin + Simvastatin</td></tr><tr><td>Vytorin</td><td>Simvastatin + Ezetimibe</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticholesteremic-agents">Anticholesteremic Agents</a></li>
<li><a href="/mesh/hydroxymethylglutaryl-coa-reductase-inhibitors">Hydroxymethylglutaryl-CoA Reductase Inhibitors</a></li>
<li><a href="/mesh/hypolipidemic-agents">Hypolipidemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>79902-63-9</td></tr><tr><th>Weight</th><td>Average: 418.5662<br>Monoisotopic: 418.271924326</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>38</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>RYMZZMVNJRMUDD-HGQWONQESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactones</td></tr><tr><th>Subclass</th><td>Delta Valerolactones</td></tr><tr><th>Direct parent</th><td>Delta Valerolactones</td></tr><tr><th>Alternative parents</th><td>Oxanes; Dicarboxylic Acids and Derivatives; Secondary Alcohols; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>oxane; dicarboxylic acid derivative; secondary alcohol; carboxylic acid ester; carboxylic acid derivative; ether; polyamine; enolate; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the delta valerolactones. These are cyclic organic compounds containing a 1-hydroxy-3,4,5,6-tetrahydro-1,2-thiazin-1- one moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia. </td></tr><tr><th>Pharmacodynamics</th><td>Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. Simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B.</td></tr><tr><th>Mechanism of action</th><td>Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.</td></tr><tr><th>Absorption</th><td>Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the availability of the drug in the systemic is low. Peak plasma concentration occurs 1.3 - 2.4 hours after administration. </td></tr><tr><th>Volume of distribution</th><td><p>Simvastatin can cross the blood-brain-barrier.</p></td></tr><tr><th>Protein binding</th><td>Both simvastatin and its &#946;-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, simvastatin is a substrate for CYP3A4. The major active metabolites of simvastatin are &#946;-hydroxyacid metabolite and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Simvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00388">simvastatin hydroxy acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/390">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.</td></tr><tr><th>Half life</th><td>3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions that lead to discontinuation of therapy include gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%).  </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Simvastatin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Kinesin-like protein KIF6<br>Gene symbol: KIF6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q6ZMV9" target="_blank">Q6ZMV9 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs20455" target="_blank">rs20455 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18222353" target="_blank" title="Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ, Pfeffer MA, White TJ, Braunwald E, Shepherd J, Devlin JJ, Sacks FM: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43.">18222353 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>3-hydroxy-3-methylglutaryl-coenzyme A reductase<br>Gene symbol: HMGCR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P04035" target="_blank">P04035 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs17244841" target="_blank">rs17244841 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Reduced response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15199031" target="_blank" title="Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004 Jun 16;291(23):2821-7.">15199031 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9475</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9422</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5951</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8508</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7335</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8387</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8435</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.835</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9254</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7513</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9307</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.792
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9408
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9657
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0061 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8921
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8573
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Synthon pharmaceuticals ltd</li>
<li>Accord healthcare inc</li>
<li>Aurobindo pharma ltd</li>
<li>Dr reddys laboratories inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Lupin ltd</li>
<li>Matrix laboratories ltd</li>
<li>Perrigo r and d co</li>
<li>Ranbaxy laboratories ltd</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Merck research laboratories div merck co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.accord-healthcare.com">Accord Healthcare</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li>Aeropharm Technology LLC</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://www.blurx.us">Blu Pharmaceuticals LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Coupler Enterprises Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li>DispenseXpress Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.intaspharma.com">Intas Pharmaceuticals Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Laboratorios Belmac SA</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li>MSP Distribution Services LLC</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Northstar Rx LLC</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td> 5 mg, 10 mg, 20 mg, 40 mg, 80 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Increased risk of rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. </td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy.</td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02703">Fusidic Acid</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions. 
</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may increase the effect and toxicity of simvastatin. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects. </td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06335">Saxagliptin</a></td><td>Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant. </td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08816">Ticagrelor</a></td><td>Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06273">Tocilizumab</a></td><td>Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid drastic changes in dietary habit.</li>
<li>Avoid taking with grapefruit juice.</li></ul></td></tr></tbody></table>